Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy

AIDS

Volumn 14, Issue 2, 2000, Pages 181-187

  Nieuwkerk, Pythia T ^a,f   Gisolf, Elisabeth H ^c   Colebunders, Robert ^d   Wu, Albert W ^e   Danner, Sven A ^b,c   Sprangers, Mirjam A ^a  

^a Department of Medical Psychology ^*  (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c Natl AIDS Therapy Evaluation Centre   (Netherlands)

^d INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Antiretroviral therapy; Protease inhibitor; Quality of life; Randomized clinical trial; Ritonavir; Saquinavir

Indexed keywords

RITONAVIR; SAQUINAVIR; STAVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRESS SYNDROME; FATIGUE; FEMALE; FITNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MULTICENTER STUDY; PERCEPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOCIAL BEHAVIOR; SYMPTOM; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RITONAVIR; SAQUINAVIR; STAVUDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0034001846     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200001280-00014     Document Type: Article

References (18)

1. 1. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996, 334:1011-1017.
2. 2. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
3. 3. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
4. 4. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1997, 351:543-549.
5. 5. Cohen C, Revicki DA, Nabulsi A, Sarocco PW, Jiang P. A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. AIDS 1998, 12:1495-1502.
6. 6. Revicki D, Swartz C. Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir-zalcitabine therapy for advanced HIV-infection. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [Abstract 458].
7. 7. Coplan P, Pegion J, Cook JR, et al. Impact of indinavir with zidovudine and lamivudine on the quality of life of HIV-positive patient with < 50 CD4 count. 12th World AIDS Conference. Geneva, June-July 1998 [Abstract 14339].
8. 8. Gisolf EH, Jurriaans S, Pelgrom J, et al. Treatment with ritonavir/ saquinavir or ritonavir/saquinavir/stavudine in HIV-1 infected individuals. The effect of treatment intensification. AIDS, in press.
9. 9. Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study. Med Care 1991, 29:786-798.
10. 10. Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res 1997, 6:481-493.
11. 11. Wu AW, Hays RD, Kelly S, Malitz F, Bozette SA. Application of the Medical Outcomes Study health-related quality of life measures in HIV/AIDS. Qual Life Res 1997, 6:531-554.
12. 12. De Boer J, Van Dam F, Sprangers M, Frissen J, Lange J. A longitudinal study on the quality of life of symptomatic HIV-infected patients (CDC IV) in a trial of zidovudine versus zidovudine and interferon. AIDS 1993, 7:947-953.
13. 13. De Boer J, Sprangers M, Aaronson N, Lange J, Van Dam F. The feasibility, reliability and validity of the EORTC QLQ-C30 in assessing the quality of life of patients with a symptomatic HIV infection or AIDS (CDC IV). Psych Health 1994, 9:65-77.
14. 14. Altman DG. Practical statistics for medical research. London: Chapman and Hall; 1991.
15. 15. Hirschel B, Francioli P. Progress and problems in the fight against AIDS. N Engl J Med 1998, 338:906-908.
16. 16. Schechter S, Struchiner CJ, Harrison LH. Protease inhibitors as initial therapy for individuals with an intermediate risk of HIV disease progression: is more necessarily better? AIDS 1999, 13:97-102.
17. 17. Burman WJ, Reves RR, Cohn DL. The case for conservative management of early HIV disease. JAMA 1998, 280:93-95.
18. 18. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.